<DOC>
	<DOCNO>NCT02859480</DOCNO>
	<brief_summary>This study prospective , randomize , open-label , single-center trial design compare 30 month-safety efficacy low-dose ( 5mg/dL ) high-dose ( 20mg/dL ) rosuvastatin treatment patient coronary artery disease percutaneous coronary intervention newer drug-eluting stent .</brief_summary>
	<brief_title>Dose-dependent Effect Rosuvastatin Long-term Clinical Outcomes After PCI</brief_title>
	<detailed_description>With development new generation drug-eluting stent , percutaneous coronary intervention ( PCI ) feasible treatment patient coronary artery disease . However , stent failure include in-stent restenosis stent thrombosis still problematic . Moreover , neoatherosclerosis , atherosclerotic process develop neointima within implanted stent , report associate neoatherosclerotic plaque rupture contribute development acute coronary syndrome patient drug-eluting stent ( DES ) implantation . In perspective , recent AHA/ACC ESC guideline recommend high-dose ( intensity ) statin therapy patient perform PCI . However , efficacy high-dose ( intensity ) statin therapy cardiovascular outcome still controversial . Several meta-analysis fail show benefit high-dose ( intensity ) statin therapy reduce mortality . Moreover , clear evidence benefit high-dose ( intensity ) statin therapy yet demonstrate East Asian patient . This trial design compare 30 month-safety efficacy low-dose ( 5mg/dL ) high-dose ( 20mg/dL ) rosuvastatin treatment patient coronary artery disease PCI era newer generation DES era .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Patients underwent percutaneous coronary intervention drugeluting stent ; Taking drug influence lipid profile ( eg . Niacin , Fibrates ; Serum creatinine level &gt; 2.0 mg/dL Serum aspartate transaminase &gt; 3 time upper limit normal Serum alanine transaminase &gt; 3 time upper limit normal Having anaphylactic reaction Rosuvastatin ; Having contraindication Rosuvastatin ; Having plan pregnant ; Having life expectancy le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rosuvastatin Calcium</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Drug-Eluting Stents</keyword>
	<keyword>Patient Outcome Assessment</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Hyperlipidemias</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Hydroxymethylglutaryl-CoA Reductase Inhibitors</keyword>
	<keyword>Anticholesteremic Agents</keyword>
	<keyword>Hypolipidemic Agents</keyword>
	<keyword>Lipid Regulating Agents</keyword>
</DOC>